S
Susan Ashton
Researcher at AstraZeneca
Publications - 38
Citations - 5092
Susan Ashton is an academic researcher from AstraZeneca. The author has contributed to research in topics: T790M & Gefitinib. The author has an hindex of 21, co-authored 37 publications receiving 4441 citations.
Papers
More filters
Journal ArticleDOI
AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer
Darren Cross,Susan Ashton,Serban Ghiorghiu,Cath Eberlein,Caroline A. Nebhan,Paula J. Spitzler,Jonathon P. Orme,M. Raymond V. Finlay,Richard A. Ward,Martine J. Mellor,Gareth D Hughes,Amar Rahi,Vivien Jacobs,Monica Red Brewer,Eiki Ichihara,Jing Sun,Hailing Jin,Peter Ballard,Katherine Al-Kadhimi,Rachel Rowlinson,Teresa Klinowska,Graham Richmond,Mireille Cantarini,Dong Wan Kim,Malcolm R Ranson,William Pao +25 more
TL;DR: A novel structurally distinct third-generation EGFR TKI that irreversibly and selectively targets both sensitizing and resistant T790M(+) mutant EGFR while harboring less activity toward wild-type EGFR is reported.
Journal Article
ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy.
A. E. Wakeling,Simon P. Guy,James R. Woodburn,Susan Ashton,Brenda J. Curry,Andrew Barker,Keith Hopkinson Gibson +6 more
TL;DR: In studies with mice bearing a range of human tumor-derived xenografts, ZD1839 given p.o. once a day inhibited tumor growth in a dose-dependent manner and indicated that continuous once-a-day dosing might be a suitable therapeutic regimen.
Journal ArticleDOI
Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer.
Barker Andrew John,Keith Hopkinson Gibson,Walter Grundy,Godfrey Andrew Aydon,Jeffrey J Barlow,Mark P Healy,J. R. Woodburn,Susan Ashton,Brenda Curry,Lynn Scarlett,Lianne Henthorn,Laura Richards +11 more
TL;DR: ZD 1839 has suitable properties for use as a clinically effective drug and shows activity against human tumours and the use of pharmacokinetic data in the development of ZD1839 is discussed.
Journal ArticleDOI
Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor
M. Raymond V. Finlay,Mark J. Anderton,Susan Ashton,Peter Ballard,Paul A. Bethel,Matthew R. Box,Robert Hugh Bradbury,Simon J. Brown,Sam Butterworth,Andrew D. Campbell,Christopher G. Chorley,Nicola Colclough,Darren Cross,Gordon S. Currie,Matthew Grist,Lorraine A. Hassall,George B. Hill,Daniel S. James,Michael James,Paul D. Kemmitt,Teresa Klinowska,Gillian M. Lamont,Scott G. Lamont,Nathaniel G. Martin,Heather L. McFarland,Martine J. Mellor,Jonathon P. Orme,David Perkins,Paula Perkins,Graham Richmond,Peter D. Smith,Richard A. Ward,Michael J. Waring,David Whittaker,Stuart L. Wells,Gail L. Wrigley +35 more
TL;DR: Following observations of significant tumor inhibition in preclinical models, the clinical candidate AZD9291 was administered clinically to patients with T790M positive EGFR-TKI resistant NSCLC and early efficacy has been observed, accompanied by an encouraging safety profile.
Journal ArticleDOI
Vascular Endothelial Growth Factor Receptors VEGFR-2 and VEGFR-3 Are Localized Primarily to the Vasculature in Human Primary Solid Cancers
Neil R. Smith,Dawn Baker,Neil H. James,K Ratcliffe,Martin Jenkins,Susan Ashton,Graham Sproat,Ruth Swann,Neil D. Gray,Anderson J. Ryan,Juliane M. Jürgensmeier,Chris Womack +11 more
TL;DR: The upregulation of VEG FR-3 on tumor blood vessels indicates a potential additional antiangiogenic effect for dual VEGFR-2/VEGFR-3–targeted therapy.